The Biological Function of TUSC7/miR-1224-3p Axis in Triple-Negative Breast Cancer
Bo-Hao Zheng,Zhi-Xian He,Juan Zhang,Jing-Jing Ma,Hong-Wei Zhang,Wei Zhu,Zhi-Min Shao,Xiao-Jian Ni
DOI: https://doi.org/10.2147/CMAR.S305865
2021-07-18
Cancer Management and Research
Abstract:Bo-Hao Zheng, 1, 2, &ast Zhi-Xian He, 3, &ast Juan Zhang, 4, &ast Jing-Jing Ma, 5, &ast Hong-Wei Zhang, 1, 2 Wei Zhu, 1, 2 Zhi-Min Shao, 6 Xiao-Jian Ni 1, 2 1 Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China; 2 Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China; 3 Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, 226001, People's Republic of China; 4 Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, 200032, People's Republic of China; 5 State Key Laboratory of Reproductive Medicine, Department of Breast Surgery, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University, Nanjing, 210004, People's Republic of China; 6 Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Cancer Center and Cancer Institute, Fudan University, Shanghai, 200032, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiao-Jian Ni Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China Tel/Fax +86-21-64041990 Email Zhi-Min Shao Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Cancer Center and Cancer Institute, Fudan University, Shanghai, 200032, People's Republic of China Tel/Fax +86-21-64175590 Email Background: Triple-negative breast cancers (TNBC), comprising about 20% of breast cancers, have a poor prognosis. Currently, there is no effective target therapy for TNBC. LncRNA TUSC7 has been identified as a tumor suppressor in osteosarcoma and colorectal cancer. In this study, we investigated the clinical significance and the biological function of TUSC7 in breast cancer. Methods: We retrospectively evaluated the expression level and clinical significance of TUSC7 in 90 paired breast cancer tissues and normal tissues. The proliferation, migration, and invasion assays were performed to investigate the biological function of TUSC7 in breast cancer. Finally, microarray, a luciferase reporter assay, and quantitative real-time polymerase chain reaction (qPCR) were used to explore the potential underlying mechanism of tumor suppressor role of TUSC7. Results: Low TUSC7 expression was found to be an independent prognostic factor of poor overall survival (OS) in TNBC patients. Ectopic expression of TUSC7 inhibited tumor cell growth both in vitro and in vivo. TUSC7 overexpression significantly promoted the sensitivity of MDA-MB-468 cells to paclitaxel and carboplatin. In terms of the mechanism, TUSC7 might perform its biological function through binding with miR-1224-3P and regulating its expression level. Besides, genes in cell cycle pathways, such as BUB3 (budding uninhibited by benzimidazoles 3) and TGF-ß (targeting transforming growth factor β) pathways were downregulated, and genes involved in the MAPK (mitogen-activated protein kinase) (TGFBR2, transforming growth factor-beta receptor 2), PI3K-AKT (phosphoinositide 3-kinase- AKT serine/threonine kinase 1) and NF-κB (nuclear factor-kappa B subunit) pathways were upregulated in TUSC7 knockdown MDA-MB-231 cells. Conclusion: The low TUSC7 expression is an independent prognostic factor of poor OS of TNBC patients. TUSC7 might inhibit breast cancer cell growth and metastasis both in vitro and vivo through binding with miR-1224-3P and regulating MAPK, PI3K/AKT, and NF-κB signaling pathways. Keywords: TUSC7, long non-coding RNA, MiR-1224-3P, triple-negative breast cancer, prognosis Dysregulation of long non-coding RNAs (lncRNAs) of lncRNAs was involved in various human diseases, including cancer. 1–5 A previous report demonstrated the potential role of lncRNA in the progression of breast cancer. 6 Triple-negative breast cancer (TNBC) makes up about 20% of whole breast cancers. 7 , 8 Compared with other types of breast cancer, TNBC is associated with early recurrence and significantly shorter survival. 9–11 The genes of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) were not expressed in TNBC. While trastuzumab targets HER2 and endocrine therapy targets the -Abstract Truncated-
oncology